Molecular Psychiatry
August 4, 2026
Kim P. C. Kuypers, Natasha L. Mason, Aurelie Carlier et al.
Women experience a disproportionate burden of affective and stress-related disorders, with symptom variability shaped by endocrine transitions across the menstrual cycle, pregnancy, postpartum, and menopause. Although psychedelic-assisted therapies are increasingly investigated for these conditions, hormonal state represents a largely unaccounted determinant of variability in exposure,...
The Brown University Psychopharmacology Update
August 3, 2026
Individuals with cocaine use disorder who received a single dose of psilocybin combined with psychotherapy showed greater reductions in cocaine use relative to active placebo with psychotherapy, a randomized trial has found. No serious adverse events were reported during the trial.
Journal of Psychopharmacology
August 3, 2026
Where is the sweet spot for psychedelic-enhanced fear extinction? An integrative quantitative synthesis of dose-effect patterns in rodent models.
Addiction
August 3, 2026
Mathieu Seynaeve, Fiona Dunbar, Anna O. Ermakova et al.
BACKGROUND AND AIMS: This study qualitatively explored psychological change processes as described by participants and therapists within a phase 2a clinical trial evaluating the safety, tolerability, and preliminary efficacy of a single dose of intranasal 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT; BPL-003) administered alongside psychological support and manualised cognitive behavioural...
Frontiers in Neuroscience
August 3, 2026
Kim P. C. Kuypers
Psychedelic-assisted therapy has shown rapid and durable benefits across multiple psychiatric conditions, yet the mechanisms underlying these effects remain incompletely understood. Full-dose psychedelic sessions simultaneously engage serotonergic neurochemistry, high-intensity subjective experience, and autonomic-interoceptive physiology, making it difficult to determine which components are...
British Journal of Mental Health Nursing
August 2, 2026
Rachel Sinclair
Depression remains a significant public health concern worldwide and many individuals do not achieve adequate symptom relief from conventional treatments such as antidepressants and psychological therapies. Interest has therefore increased in alternative interventions, including psilocybin microdosing. This article aimed to critically review the current evidence regarding the use of psilocybin...
Journal of Affective Disorders
August 1, 2026
Taro Kishi, Kenji Sakuma, Masakazu Hatano et al.
This systematic review and meta-analysis of six randomized controlled trials aimed to investigate the temporal changes in the efficacy and safety of psilocybin treatment for major depressive disorder (MDD). Separate meta-analyses were conducted for standard-dose psilocybin (25 mg/session, or 20-30 mg/70 kg/session) and low-dose psilocybin (10 mg/session or 15.05 mg/70 kg/session) subgroups....
Communications medicine
July 30, 2026
Stacey B. Armstrong, Adam W. Levin, Nathan D. Sepeda et al.
Psilocybin-assisted therapy (PAT) shows promise for treating PTSD in adults but hasn't been studied in U.S. military Veterans, who face higher symptom severity and suicide risk. This open-label pilot trial evaluated the safety and feasibility of PAT in Veterans with severe, treatment-resistant PTSD. The clinical trial was pre-registered at ClinicalTrials.gov (NCT05554094). The eligibility...
July 27, 2026
Asher Wenig, David B Newman
preprint
This project will use a PRISMA-guided systematic review and meta-analysis to examine whether age moderates anxiety and depression outcomes following psychoactive-assisted treatments. In this review, psychoactive-assisted treatments are defined as clinically structured treatments involving classic serotonergic psychedelics, MDMA, ketamine, or esketamine. The term is intentionally broader than...
npj Mental Health Research
July 27, 2026
Jennifer Swainson, P. Grewal, S. Polard et al.
This scoping review maps literature for use of ketamine or esketamine with psychotherapy for depression or depressive symptoms. Forty-seven studies were identified including 4/47 (9%) randomized controlled trials, 4/47 (9%) open label trials, 27/47 (57%) observational or retrospective studies, and 12/47 (26%) individual case reports. Studies were categorized as Ketamine/Esketamine Combined with...